Immunotherapy for renal carcinoma: theoretical basis and current standard of care
- PMID: 11136291
- PMCID: PMC2015010
- DOI: 10.1046/j.1365-2125.2000.00300.x
Immunotherapy for renal carcinoma: theoretical basis and current standard of care
Figures
Similar articles
-
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.J Clin Oncol. 2006 Dec 10;24(35):5584-92. doi: 10.1200/JCO.2006.08.1638. J Clin Oncol. 2006. PMID: 17158544 Review.
-
The role of adoptive immunotherapy in solid cancers.Neth J Med. 1997 Feb;50(2):47-68. doi: 10.1016/s0300-2977(96)00083-6. Neth J Med. 1997. PMID: 9050332 Review. No abstract available.
-
Immunotherapy for renal cell carcinoma.Hematol Oncol Clin North Am. 2011 Aug;25(4):793-812. doi: 10.1016/j.hoc.2011.04.010. Hematol Oncol Clin North Am. 2011. PMID: 21763968 Review.
-
Renal cancer immunotherapy: a ray of hope or regression to the mean?Cancer Invest. 2000;18(5):490-1. doi: 10.3109/07357900009032820. Cancer Invest. 2000. PMID: 10834033 No abstract available.
-
Renal cell cancer: is immunotherapy dead?Ann Oncol. 2007 Jul;18 Suppl 9:ix94-7. doi: 10.1093/annonc/mdm302. Ann Oncol. 2007. PMID: 17631604 Review. No abstract available.
References
-
- Office of Population Census and Surveys. Mortality Statistics DH2 No 20. London: HMSO; 1995.
-
- Richie AWS, de Kernion JB. The natural history and clinical features of renal carcinoma. Semin Nephrol. 1987;7:131–139. - PubMed
-
- Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med. 1996;355:865–875. - PubMed
-
- Evenson TC, Cole WH. Spontaneous Regression of Cancer. Philadelphia: W.B. Saunders; 1996. pp. 11–87.
-
- Bloom HJG. Endocrine Therapy of Malignant Disease. Philadelphia: W.B. Saunders; 1972. Renal cancer; pp. 339–367.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical